S&P 500
5.071,63 +1,08 (+0,02%) Nasdaq
15.712,75 +16,11 (+0,10%) NIKKEI 225
38.460,08 +907,92 (+2,42%) Dólar/Euro
1,0701 0,0000 (-0,00%) Petróleo Brent
88,04 +0,02 (+0,02%) Bitcoin EUR
59.698,18 -2.271,70 (-3,67%)
Insmed Incorporated (INSM)
Después del cierre:
Insmed Incorporated
700 US Highway 202/206
Bridgewater, NJ 08807
United States
908 977 9900
https://www.insmed.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 912
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. William H. Lewis J.D., M.B.A. | President, CEO & Chairman | 1,59M | 1,11M | 1969 |
| Ms. Sara M. Bonstein M.B.A. | Chief Financial Officer | 810,4k | N/A | 1981 |
| Mr. Roger Adsett M.B.A. | Chief Operating Officer | 1,01M | N/A | 1969 |
| Mr. John Drayton Wise M.B.A. | Chief Commercial Officer | 888,85k | N/A | 1975 |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer | 872,29k | 179,49k | 1964 |
| Mr. Brian K. Kaspar Ph.D. | Chief Scientific Officer | N/A | N/A | 1974 |
| Eleanor Barisser | Associate Director of Investor Relations | N/A | N/A | N/A |
| Mr. Michael Alexander Smith J.D. | Chief Legal Officer & Corporate Secretary | N/A | N/A | 1978 |
| Mandy Fahey | Executive Director of Corporate Communications | N/A | N/A | N/A |
| Ms. S. Nicole Schaeffer M.B.A. | Chief People Strategy Officer | 660,81k | 1,18M | 1968 |
Descripción
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Gobierno corporativo
El ISS Governance QualityScore de Insmed Incorporated, a día 1 de abril de 2024, es 6. Las puntuaciones base son Auditoría: 6; Tablero: 5; Derechos de los accionistas: 9; Compensación: 5.
